July 2026

From Target to Hit: How Integrated Discovery Biology Services Are Accelerating Early Drug Discovery

The journey to bring a new medicine to the market is incredibly long and very expensive. It can take over a decade and cost billions of dollars to turn a scientific idea into a pill you can buy at the pharmacy. The very first step in this long journey is known as the “target-to-hit” phase, a core part of drug discovery biology. This is the starting line: the time when scientists figure out exactly how a disease works and find the very first chemicals that might be able to treat it.

The speed and accuracy of this early stage often decide if a new drug program will succeed or fail. As we learn more about complex diseases, drug companies can no longer work in isolated teams. Instead, they need to connect biology and chemistry smoothly to ensure that only the best, safest chemical compounds move forward in the testing process.

Finding and Proving the Target: The Biological Lock

Every successful drug discovery program begins with a proven biological “target.” You can think of a target as a specific lock on a door inside the human body. Usually, this target is a protein or an enzyme that causes a disease to happen. If a person has cancer, for example, the target might be a protein that is telling the cancer cells to multiply too fast.

However, simply finding a target is not enough; scientists must prove that it actually matters. This step is called target validation. It is the best way to prevent expensive failures later on. If a target does not really affect the disease, any drug made to interact with it will fail when it is tested on patients.

To prove the target is correct, scientists use special genetic tools. They will go into living cells and turn off the target protein completely. Then, they watch what happens. If turning off the protein causes the cancer cells to stop growing, the scientists know they have found the right lock. Now, they just need to build a key to fit it.

Creating the Right Tests: Assay Development

After scientists are confident they have the right target, they focus on creating chemical tests. In the science world, these tests are called assays. An assay is a reliable, repeatable test that gives scientists a clear signal when a chemical compound successfully interacts with the target.

For example, a good assay might cause a liquid to glow or change color when a chemical successfully blocks the disease-causing protein.

Assay development usually falls into two main categories: biochemical and cell-based. Biochemical assays test the target in a simple, controlled plastic tube without any living cells involved. This is a very fast way to see if a chemical attaches directly to the target.

However, medicines must eventually work inside a living, crowded human body. Because of this, scientists also build cell-based assays. These tests use living cells to see how the chemical affects the entire cell’s behavior. Finding the right balance between fast, simple tests and complex, real-world cell tests requires a lot of expert knowledge.

Testing Thousands of Chemicals: High-Throughput Screening

Once the chemical tests are ready, the real screening begins. High-Throughput Screening (HTS) is the main engine of early drug discovery. Imagine trying to test a million different keys on a lock by hand; it would take a lifetime. HTS uses advanced robots and fast computer systems to do the heavy lifting.

Using small plastic plates that contain hundreds of tiny wells, robots can drop a different chemical into each well. The machines can test hundreds of thousands of chemicals against the target in just a few weeks. The main goal of this robotic screening is to cast a massive net.

Scientists want to scan as many different chemicals as possible to find a small group of “active” chemicals that trigger a positive signal in the test.

Weeding Out the Fakes: Hit Triage

After the robotic screening is done, scientists get a list of chemicals that seem to work. But this list is never perfect. Many of the chemicals on it are “false positives.”

For instance, a chemical might just turn the liquid cloudy, confusing the machines and making the test look successful when it is not. Other chemicals might act like sticky glue, attaching to everything randomly instead of fixing the specific disease target.

This stage is about weeding out the fakes. Scientists run different types of backup tests to double-check the results. Chemists also look closely at the shape of the chemicals. A true “hit” must only affect the specific target, and it must have a chemical structure that scientists can safely turn into a medicine later on.

Conclusion

Moving smoothly from finding a target to confirming a true chemical hit takes a lot of different skills. It requires expensive robots, complex testing labs, and highly trained biologists and chemists. For many drug companies, building all these labs and hiring all these experts is just too expensive.

This is where partnering with outside lab experts becomes a huge advantage. By using comprehensive Discovery Biology services, drug developers can smoothly move their projects past early roadblocks. Working with specialized experts breaks down the walls between different science teams. The scientists making the tests work directly with the robot operators and the chemists checking the final hits.